Davidson & Garrard’s Medical Properties Trust MPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q3
$344K Hold
26,200
0.08% 141
2017
Q2
$337K Hold
26,200
0.08% 144
2017
Q1
$338K Hold
26,200
0.08% 144
2016
Q4
$322K Hold
26,200
0.08% 141
2016
Q3
$387K Sell
26,200
-100
-0.4% -$1.51K 0.1% 135
2016
Q2
$400K Hold
26,300
0.1% 143
2016
Q1
$341K Buy
26,300
+500
+2% +$5.7K 0.09% 140
2015
Q4
$297K Buy
25,800
+2,200
+9% +$25.1K 0.07% 156
2015
Q3
$261K Buy
23,600
+5,800
+33% +$72K 0.07% 159
2015
Q2
$233K Hold
17,800
0.05% 170
2015
Q1
$262K Buy
17,800
+1,000
+6% +$14.9K 0.06% 163
2014
Q4
$232K Buy
16,800
+4,000
+31% +$53.6K 0.05% 164
2014
Q3
$157K Sell
12,800
-1,100
-8% -$14.6K 0.04% 169
2014
Q2
$184K Buy
13,900
+1,000
+8% +$13.3K 0.04% 173
2014
Q1
$165K Hold
12,900
0.04% 176
2013
Q4
$158K Hold
12,900
0.04% 185
2013
Q3
$157K Hold
12,900
0.04% 175
2013
Q2
$185K Buy
+12,900
New +$203K 0.06% 164

Other funds holding MPT

Davidson & Garrard's MPT Position: Q3 2017 in Review

Davidson & Garrard held its Medical Properties Trust (MPT) position steady in Q3 2017 at 26,200 shares worth $344K. The position accounts for 0.08% of the portfolio, ranked #141.

Davidson & Garrard first reported a position in MPT in Q2 2013 and has held it in 18 quarters since. The position peaked at $400K in Q2 2016. 331 funds tracked by Wall St. Rank hold MPT as of Q3 2017.

  • Davidson & Garrard held 26,200 shares of Medical Properties Trust worth $344K as of Q3 2017.
  • Davidson & Garrard left its Medical Properties Trust share count unchanged in Q3 2017.
  • Medical Properties Trust made up 0.08% of Davidson & Garrard's portfolio in Q3 2017, its #141 holding.
  • Davidson & Garrard first reported a position in Medical Properties Trust in Q2 2013 and has held it in 18 quarters since.
  • Davidson & Garrard's Medical Properties Trust position peaked at $400K in Q2 2016.
  • 331 funds tracked by Wall St. Rank held Medical Properties Trust as of Q3 2017.

Based on Davidson & Garrard's 13F filing for Q3 2017, filed 7 Nov 2017.